Citi analyst Samantha Semenkow lowered the firm’s price target on BioAge Labs (BIOA) to $5 from $7 and keeps a Neutral rating on the shares post the Q4 report. The firm anticipates the shares will remain somewhat range-bound over the next 12 months given “limited stock-moving catalysts.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOA:
- Cautious Outlook on BioAge Labs Amid Promising Developments and High Risk
- BioAge Labs, Inc.: Sell Rating Due to Discontinued Program and Uncertain Prospects
- BioAge Labs assumed with an Underweight at Morgan Stanley
- Cautious Outlook on BioAge Labs, Inc. Amid Program Discontinuation and Development Risks
- BioAge Labs initiated with a Market Perform at William Blair